NKTR-118 Shows Substantial Oral Bioavailability And Extended Half-Life In Phase 1 Clinical Data Presented At American Pain Society Meeting
New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics (Nasdaq: NKTR) this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida. In this multiple-dose Phase 1 study, oral NKTR-118 was shown to have substantial oral bioavailability with rapid absorption and an extended half-life that is up to ten times the known half-life of unPEGylated naloxone.
More: continued here
Filed under: Pain / Anesthetics on May 15th, 2008